Two studies in the New England Journal of Medicine came to differing conclusions about the utility of oral anticoagulants in patients with cancer. This might be because they enrolled the wrong patients.
A study appearing in JAMA Internal Medicine links the cost of developing a new drug to the ultimate revenue a company receives. The results suggest that curbing R&D costs may not have much effect on drug pricing at all. For the video version, click here.